ArticleOncotarget2015
eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Hydroquinidine Modulates Histopathological, Inflammatory, Apoptotic, EMT-Related, and PI3K/AKT/mTOR-Associated Markers in a DMH-Induced Rat Model of Colon Cancer.International journal of molecular sciences · 2026Article
- CBX6 and CA9 as predictive indicators and therapeutic targets in GBM.Molecular therapy. Oncology · 2026Article
- The EIF4EBP1 gene encoding 4EBP1 is transcriptionally upregulated by MYC and linked to shorter survival in medulloblastoma.Cell death discovery · 2025Article
- Advancing Colorectal Cancer Diagnostics from Barium Enema to AI-Assisted Colonoscopy.Diagnostics (Basel, Switzerland) · 2025Review
- Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.Cell death & disease · 2024Review
- Human Milk Supports Robust Intestinal Organoid Growth, Differentiation, and Homeostatic Cytokine Production.Gastro hep advances · 2024Article
- Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer.Cancer cell international · 2022Article
- Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation.Cell death discovery · 2022Article
- Translation initiation and its relevance in colorectal cancer.The FEBS journal · 2021Review
- BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.Oncology reports · 2020Article
- Article
- Article
- A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer.Journal of gastrointestinal cancer · 2019Article
- Review
- The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Oncotarget · 2017Article
- Insights into the role and regulation of TCTP in skeletal muscle.Oncotarget · 2017Article
- Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.Frontiers in oncology · 2017Review
- eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.Oncotarget · 2016Article
- Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.Oncogene · 2016Review
- 4E-BP1, a multifactor regulated multifunctional protein.Cell cycle (Georgetown, Tex.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent translation. This study is the first to demonstrate that 4E-BP1 expression correlates with colorectal cancer (CRC) progression. Compared to its expression in normal colon epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. Our previous data showed that YXM110, a cryptopleurine derivative, exhibited anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by YXM110 under hypoxic conditions, implying that cap-independent translation could be suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1α (HIF-1α) expression, which resulted in decreased downstream vascular endothelial growth factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.